MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE
The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that emp...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KROGH, Berit Olsen JENSEN, Allan EISENBACH-SCHWARTZ, Michal YOLES, Ester EGEBJERG, Jan DAVID, Carol BARUCH, Kuti |
| description | The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SG11202110990RA</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SG11202110990RA</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SG11202110990RA3</originalsourceid><addsrcrecordid>eNqNyrEKwjAUheEsDqK-QwbXQFKnjtF70gZsIknqJJQicRIt1PfHoD6A0_n4OUt26TxZY0Fcu2TFicRRfbgvHbGQeIfUevq6jyUaH3gK0Mm6hmvu0AdPaOAQSjuDk43QEWu2uI33OW9-u2Jbg3RoRZ6eQ56n8Zof-TXERqlKVkrJupZB7_68vQGUejNH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE</title><source>esp@cenet</source><creator>KROGH, Berit Olsen ; JENSEN, Allan ; EISENBACH-SCHWARTZ, Michal ; YOLES, Ester ; EGEBJERG, Jan ; DAVID, Carol ; BARUCH, Kuti</creator><creatorcontrib>KROGH, Berit Olsen ; JENSEN, Allan ; EISENBACH-SCHWARTZ, Michal ; YOLES, Ester ; EGEBJERG, Jan ; DAVID, Carol ; BARUCH, Kuti</creatorcontrib><description>The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211028&DB=EPODOC&CC=SG&NR=11202110990RA$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211028&DB=EPODOC&CC=SG&NR=11202110990RA$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KROGH, Berit Olsen</creatorcontrib><creatorcontrib>JENSEN, Allan</creatorcontrib><creatorcontrib>EISENBACH-SCHWARTZ, Michal</creatorcontrib><creatorcontrib>YOLES, Ester</creatorcontrib><creatorcontrib>EGEBJERG, Jan</creatorcontrib><creatorcontrib>DAVID, Carol</creatorcontrib><creatorcontrib>BARUCH, Kuti</creatorcontrib><title>MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE</title><description>The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAUheEsDqK-QwbXQFKnjtF70gZsIknqJJQicRIt1PfHoD6A0_n4OUt26TxZY0Fcu2TFicRRfbgvHbGQeIfUevq6jyUaH3gK0Mm6hmvu0AdPaOAQSjuDk43QEWu2uI33OW9-u2Jbg3RoRZ6eQ56n8Zof-TXERqlKVkrJupZB7_68vQGUejNH</recordid><startdate>20211028</startdate><enddate>20211028</enddate><creator>KROGH, Berit Olsen</creator><creator>JENSEN, Allan</creator><creator>EISENBACH-SCHWARTZ, Michal</creator><creator>YOLES, Ester</creator><creator>EGEBJERG, Jan</creator><creator>DAVID, Carol</creator><creator>BARUCH, Kuti</creator><scope>EVB</scope></search><sort><creationdate>20211028</creationdate><title>MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE</title><author>KROGH, Berit Olsen ; JENSEN, Allan ; EISENBACH-SCHWARTZ, Michal ; YOLES, Ester ; EGEBJERG, Jan ; DAVID, Carol ; BARUCH, Kuti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SG11202110990RA3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>KROGH, Berit Olsen</creatorcontrib><creatorcontrib>JENSEN, Allan</creatorcontrib><creatorcontrib>EISENBACH-SCHWARTZ, Michal</creatorcontrib><creatorcontrib>YOLES, Ester</creatorcontrib><creatorcontrib>EGEBJERG, Jan</creatorcontrib><creatorcontrib>DAVID, Carol</creatorcontrib><creatorcontrib>BARUCH, Kuti</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KROGH, Berit Olsen</au><au>JENSEN, Allan</au><au>EISENBACH-SCHWARTZ, Michal</au><au>YOLES, Ester</au><au>EGEBJERG, Jan</au><au>DAVID, Carol</au><au>BARUCH, Kuti</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE</title><date>2021-10-28</date><risdate>2021</risdate><abstract>The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_SG11202110990RA |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A59%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KROGH,%20Berit%20Olsen&rft.date=2021-10-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESG11202110990RA%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |